Faculty, Student Works School of Dentistry
http://hdl.handle.net/10713/4792
2024-03-15T05:31:15ZInfluence of Imidazolium-Based Ionic Liquids on Acrylic Denture Base Materials
http://hdl.handle.net/10713/21543
Influence of Imidazolium-Based Ionic Liquids on Acrylic Denture Base Materials
Garcia, Isadora Martini; Virgina, Serra de Souza; Scholten, Jackson Damiani; Sampaio de Melo, Mary Anne; Mezzomo Collares, FabrÃcio
IADR - New Orleans, March 13, 2024
2024-03-13T00:00:00ZEffects of Environmental Enrichment on Visceral Sensitivity and Brain Connectivity in a Mouse Model of Chronic Overlapping Pain Conditions
http://hdl.handle.net/10713/21009
Effects of Environmental Enrichment on Visceral Sensitivity and Brain Connectivity in a Mouse Model of Chronic Overlapping Pain Conditions
MIchael, Keaser; Hanson, Shelby; Scott, Alison June; Traub, Richard J.; Da Silva, Joyce T.
Neuroscience 2023. November 11, 2023
2023-11-11T00:00:00ZSex differences in diffuse noxious inhibitory control (DNIC) are mediated by the rostral anterior cingulate cortex (rACC) periaqueductal gray (PAG) circuit
http://hdl.handle.net/10713/20965
Sex differences in diffuse noxious inhibitory control (DNIC) are mediated by the rostral anterior cingulate cortex (rACC) periaqueductal gray (PAG) circuit
Rocha, Igor Rafael Correia; Santo, Renan; Zhang, Youping; Da Silva, Joyce T.; Ro, Jin Y.
CAPCR Symposium, October 25, 2023
2023-10-25T00:00:00ZMetformin and other metabolic inhibitors attenuate neuropathic pain and tumor growth in mice with paraneoplastic syndrome and CIPN
http://hdl.handle.net/10713/20963
Metformin and other metabolic inhibitors attenuate neuropathic pain and tumor growth in mice with paraneoplastic syndrome and CIPN
Kuppusamy, Panjamurthy; Haque, Mamunui; Melemedijian, Ohannes
Chemotherapy-induced peripheral neuropathy (CIPN) and paraneoplastic neurological
syndrome are two conditions that can cause significant pain and discomfort in cancer
patients. CIPN is a common side effect of certain chemotherapeutics and can result in
numbness, tingling, and pain. Paraneoplastic neurological syndrome, on the other hand, is a
rare disorder that occurs when cancer-fighting antibodies attack parts of the nervous
system. Both neuropathies can persist which can adversely affect the quality of life and the
rehabilitation of cancer patients. Unfortunately, therapies that can alleviate tumor or
chemotherapy-induced neuropathic pain that do not interfere with tumor growth do not
currently exist. The main goal of this study was to identify a therapeutic strategy that can
achieve both anti-tumor and analgesic effects. The chemotherapeutic, bortezomib, has been
shown to induce aerobic glycolysis in sensory neurons which lead to bortezomib-induce
neuropathic pain. Aerobic glycolysis is also a hallmark of cancer cells, suggesting a common
metabolic vulnerability. Paraneoplastic neuropathies are commonly associated with lung
cancers. Hence, we used Lewis Lung Carcinoma cells (LLC1) to develop a mouse model of
paraneoplastic neuropathy. We hypothesized that blocking metabolic pathways could
alleviate CIPN and paraneoplastic neuropathic pain without compromising on tumor control.
To test our hypothesis, we demonstrated that mice implanted with LLC1 developed
significant allodynia. Treatment with bortezomib attenuated tumor growth but exacerbated
the neuropathic pain. However, co-treatment with metformin, which blocks bortezomib-
induced aerobic glycolysis in sensory neurons and prevents CIPN, attenuated both tumor
growth and neuropathic pain. Similarly, inhibition of lactate dehydrogenase and pyruvate
dehydrogenase kinase with oxamate and dichloroacetate respectively, also reduced tumor
growth and pain. These results suggest that targeting metabolic pathways is a promising
strategy to improve oncologic outcomes and alleviate neuropathic pain in cancer patients.
Neuroscience 2023 in Washington, D.C., November 15, 2023
2023-11-15T00:00:00Z